CNS Pharmaceuticals
CNSP
2 hedge funds and large institutions have $190K invested in CNS Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
43% less capital invested
Capital invested by funds: $335K → $190K (-$145K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $124K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $27K | +$56K | +1 | New |
|
3
Citadel Advisors
Miami,
Florida
| $13.2K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $12K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $11K | – | – | – |
|
6
UBS Group
Zurich,
Switzerland
| $2.46K | – | – | – |
|
7
Wells Fargo
San Francisco,
California
| $482 | – | – | – |
|
8
Fidelity Investments
Boston,
Massachusetts
| $200 | – | – | – |
|
|
GRP
9
Global Retirement Partners
San Rafael,
California
| $102 | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $25 | – | – | – |
|
|
GI
11
Gradient Investments
Arden Hills,
Minnesota
| $7 | – | – | – |
|
12
Osaic Holdings
Scottsdale,
Arizona
| $1 | – | – | – |
|
|
PMFA
13
Plante Moran Financial Advisors
Southfield,
Michigan
| $1 | – | – | – |
|
|
14
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$20 | – | – |
|
CNSP Hedge Fund Activity: Q1 2023 in Review
2 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q1 2023, worth a combined $190K — down 43% from $335K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CNSP positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $56K. The largest seller was PNC Financial Services Group, cutting an estimated $20.
- 2 institutional investors held CNS Pharmaceuticals (CNSP) as of Q1 2023, up from 1 in Q4 2022.
- Funds reported $190K of CNS Pharmaceuticals stock for Q1 2023, down 43% quarter-over-quarter.
- 1 fund opened new CNS Pharmaceuticals positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest CNS Pharmaceuticals buyer in Q1 2023 was Renaissance Technologies, an estimated $56K added.
- The largest CNS Pharmaceuticals seller in Q1 2023 was PNC Financial Services Group, an estimated $20 sold.
Based on aggregated 13F filings for Q1 2023.